MOMM Diagnostics GmbH
MOMM Diagnostics GmbH aims to develop a novel in-vitro diagnostic test for the early diagnosis of preeclampsia at the point-of-care. Preeclampsia affects 5-8% of all pregnancies and is one of the top five causes for maternal and infant illness and death. Early identification of the condition is crucial to minimize complications. PE screening, using a simple test for the definite diagnosis at the obstetrician's office helps to save lives and money.